Literature DB >> 8985324

Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope.

S Menne1, J Maschke, T K Tolle, M Lu, M Roggendorf.   

Abstract

Specific activation of T cells appears to be a prerequisite for viral clearance during hepatitis B virus (HBV) infection. The T-cell response to HBV core protein is essential in determining an acute or chronic outcome of HBV infection, but how this immune response contributes to the course of infection remains unclear. This is due to results obtained from humans, which are restricted to phenomenological observations occurring during the clinical onset after HBV infection. Thus, a useful animal model is needed. Characterization of the T-cell response to the core protein (WHcAg) of woodchuck hepatitis virus (WHV) in woodchucks contributes to the understanding of these mechanisms. Therefore, we investigated the response of woodchuck peripheral blood mononuclear cells (PBMCs) to WHcAg and WHcAg-derived peptides, using our 5-bromo-2'-deoxyuridine assay. We demonstrated WHcAg-specific proliferation of PBMCs and nylon wool-nonadherent cells from acutely WHV-infected woodchucks. Using a cross-reacting anti-human T-cell (CD3) antiserum, we identified nonadherent cells as woodchuck T cells. T-cell epitope mapping with overlapping peptides, covering the entire WHcAg, revealed T-cell responses of acutely WHV-infected woodchucks to peptide1-20, peptide100-119, and peptide112-131. Detailed epitope analysis in the WHcAg region from amino acids 97 to 140 showed that T cells especially recognized peptide97-110. Establishment of polyclonal T-cell lines with WHcAg or peptide97-110 revealed reciprocal stimulation by peptide97-110 or WHcAg, respectively. We vaccinated woodchucks with peptide97-110 or WHcAg to prove the importance of this immunodominant T-cell epitope. All woodchucks immunized with peptide97-110 or WHcAg were protected. Our results show that the cellular immune response to WHcAg or to one T-cell epitope protects woodchucks from WHV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985324      PMCID: PMC191025     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Viral mutations, TCR antagonism and escape from the immune response.

Authors:  A Franco; C Ferrari; A Sette; F V Chisari
Journal:  Curr Opin Immunol       Date:  1995-08       Impact factor: 7.486

Review 2.  The woodchuck: an animal model for hepatitis B virus infection in man.

Authors:  M Roggendorf; T K Tolle
Journal:  Intervirology       Date:  1995       Impact factor: 1.763

3.  In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection.

Authors:  P J Cote; J L Gerin
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

4.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.

Authors:  A Bertoletti; A Sette; F V Chisari; A Penna; M Levrero; M De Carli; F Fiaccadori; C Ferrari
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

5.  A 10-amino-acid linear sequence of VP1 of foot and mouth disease virus containing B- and T-cell epitopes induces protection in mice.

Authors:  P Zamorano; A Wigdorovitz; M Perez-Filgueira; C Carrillo; J M Escribano; A M Sadir; M V Borca
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

6.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

7.  Selective sensitization of peripheral blood T lymphocytes to hepatitis B core antigen in patients with chronic active hepatitis type B.

Authors:  C Ferrari; A Penna; P Sansoni; T Giuberti; T M Neri; F V Chisari; F Fiaccadori
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

8.  Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants.

Authors:  H F Löhr; W Weber; J Schlaak; B Goergen; K H Meyer zum Buschenfelde; G Gerken
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

9.  Assessment of peripheral blood mononuclear cell proliferation by [2-3H]adenine uptake in the woodchuck model.

Authors:  E Kreuzfelder; S Menne; S Ferencik; M Roggendorf; H Grosse-Wilde
Journal:  Clin Immunol Immunopathol       Date:  1996-03

10.  Protection against hepatitis B virus infection by immunization with hepatitis B core antigen.

Authors:  S Iwarson; E Tabor; H C Thomas; P Snoy; R J Gerety
Journal:  Gastroenterology       Date:  1985-03       Impact factor: 22.682

View more
  34 in total

1.  The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen.

Authors:  T T Yuan; G K Sahu; W E Whitehead; R Greenberg; C Shih
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen.

Authors:  T T Yuan; P C Tai; C Shih
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

Authors:  Jing You; Lin Zhuang; Hong-Ying Cheng; Shou-Ming Yan; Lan Yu; Jun-Hua Huang; Bao-Zhang Tang; Meng-Ling Huang; Yong-Liang Ma; Virasakdi Chongsuvivatwong; Hutcha Sriplung; Alan Geater; Yan-Wei Qiao; Rong-Xue Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 4.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

5.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

Review 6.  The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

Authors:  Michael Roggendorf; Anna D Kosinska; Jia Liu; Mengji Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2015-10-28       Impact factor: 6.915

7.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge.

Authors:  S Menne; J Maschke; M Lu; H Grosse-Wilde; M Roggendorf
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.

Authors:  Dieter Glebe; Heike Lorenz; Wolfram H Gerlich; Scott D Butler; Ilia A Tochkov; Bud C Tennant; Paul Cote; Stephan Menne
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

10.  Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.

Authors:  Mengji Lu; Xin Yao; Yang Xu; Heike Lorenz; Uta Dahmen; Haidong Chi; Olaf Dirsch; Thekla Kemper; Lifang He; Dieter Glebe; Wolfram H Gerlich; Yumei Wen; Michael Roggendorf
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.